US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

35.81

-0.4800-1.32%

Post-market: 35.810.00000.00%19:57 EDT

Volume:400.39K

Turnover:14.39M

Market Cap:425.42M

PE:- -

High:36.29

Open:36.16

Low:35.72

Close:36.29

52wk High:39.39

52wk Low:25.85

Shares:11.88M

Float Shares:11.88M

Volume Ratio:2.13

T/O Rate:3.37%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Immunocore reports third quarter financial results and provides a business update

Kura Oncology Reports Third Quarter 2025 Financial Results

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Asylum seeker released in error seen in London area, police say

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Verastem: GFH375 resulted in 41% ORR in Phase 1/2 study

Why Is Genmab Stock Trading Lower On Monday?

Benzinga_recent_news

What's Going On With Summit Therapeutics Stock On Monday?

Benzinga_recent_news

Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":35.81,"timestamp":1774641600000,"preClose":36.29,"halted":0,"volume":400387,"hourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01322678423808203,"floatShares":11880000,"shares":11880000,"eps":0,"marketStatus":"Market Closed","change":-0.48,"latestTime":"03-27 16:00:00 EDT","open":36.16,"high":36.29,"low":35.72,"amount":14394852.358289002,"amplitude":0.015707,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":36.29,"sharesOutstanding":12900000,"nav":36.65,"aum":435402000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":36.18,"preClose":36.29,"latestTime":"09:19 EDT","volume":11,"amount":397.98,"timestamp":1774617580197,"change":-0.11,"changeRate":-0.003031,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.12915,"impliedVol":0.0274,"impliedVolPercentile":0.0357},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":11880000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.12915,"shares":11880000,"dividePrice":0,"high":36.29,"amplitude":0.015707,"preClose":36.29,"low":35.72,"week52Low":25.85,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":35.81,"eps":0,"divideRate":0,"volume":400387,"delay":0,"ttmEps":0,"open":36.16,"prevYearClose":34.16,"prevWeekClose":35.79,"prevMonthClose":39.08,"prevQuarterClose":34.16,"fiveDayClose":35.79,"twentyDayClose":39.08,"sixtyDayClose":34.345},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581909528","title":"Immunocore reports third quarter financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581909528","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581909528?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430400,"startTime":"0","endTime":"0","summary":"Immunocore reports third quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182351/0/en/Immunocore-reports-third-quarter-financial-results-and-provides-a-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","IE0031619046.USD","IE00B19Z4B17.USD","ORR","LU1093756325.SGD","BK4533","ATOM","LU1093756168.USD","LU2065731478.USD","OS","LU2413666699.HKD","BK4121","BK4567","LU1721428933.USD","LU0347712357.USD","BK4599","BK4588","BK4139","PROC","CRS","LU0963586101.USD","IE00BYQQ9H92.USD","CTA","PFS","IE00B66KJ199.SGD","LU1878469433.USD","BK4548","CM","BK4147","LU2413666426.HKD","BK4007","BK4195","BK4006","IE00BFXG0V08.USD","ALT","IE00B7SZL793.SGD","BK4585","LU2211817866.USD","MTD","BK4207","BK4187","BK4097"],"gpt_icon":0},{"id":"2580780289","title":"Kura Oncology Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780289","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580780289?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:31","pubTimestamp":1762255860,"startTime":"0","endTime":"0","summary":"– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate zif","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180088/35186/en/Kura-Oncology-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","BK4139","KURA","BK4109","BK4505","ASH","ORR","LU2463526074.USD"],"gpt_icon":0},{"id":"2580936275","title":"Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580936275","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580936275?lang=en_us&edition=fundamental","pubTime":"2025-11-04 09:10","pubTimestamp":1762218600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov.  03, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3179927/0/en/Ascentage-Pharma-to-Present-Data-from-Two-Clinical-Studies-for-Bcl-2-Inhibitor-Lisaftoclax-Including-an-Oral-Report-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","BK4097","AAPG","BK4533","LU0985320562.USD","ALL","BK4107","CR","LU2355687059.USD","HR","BK4225","OS","TLS","ORR","LU2463526074.USD","BK4585","BK4161","LU1699723380.USD","LU1571399168.USD","BK4109","BK4588","ASH","BK4139"],"gpt_icon":0},{"id":"2580112412","title":"Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580112412","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580112412?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:15","pubTimestamp":1762179300,"startTime":"0","endTime":"0","summary":"Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limitin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179422/0/en/Marker-Therapeutics-Announces-Upcoming-Presentations-on-MT-601-in-Relapsed-Non-Hodgkin-and-Hodgkin-Lymphoma-at-the-67th-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HL","LENZ","LU2065731478.USD","MAR","IE00B66KJ199.SGD","BK4187","LU1718418525.SGD","BK4539","LU2463526074.USD","BK4006","BK4007","CAR","IE00B1G9WX41.USD","BK4585","LU0963586101.USD","BK4561","BK4109","IE0031619046.USD","IE00B95QR487.USD","IE00B0T0GQ85.USD","BK4139","BK4570","MT","ASH","BK4230","IE00BD0PCF45.HKD","LU0345780281.USD","CRS","BK4161","IE00B45NX917.SGD","IE00B19Z4B17.USD","CR","BK4142","LU0345780521.USD","BK4022","ORR","BK4210","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2579546872","title":"Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2579546872","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579546872?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908400,"startTime":"0","endTime":"0","summary":"Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based onprevious alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178218/0/en/Adagene-Announces-First-Patient-Dosed-in-Randomized-Dose-Optimization-Cohort-of-the-Phase-2-Study-of-Muzastotug-ADG126-in-Combination-with-KEYTRUDA-pembrolizumab-in-Microsatellite-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","IE00BLSP4239.USD","LU1941712264.USD","SOC","LU1430594728.SGD","LU1929549753.HKD","SG9999002232.USD","CRC","LU1066051811.HKD","IE00BN8TJ469.HKD","LU1974910355.USD","SG9999001176.SGD","BK4588","IE00BJT1NW94.SGD","SG9999014542.SGD","LU1989772840.SGD","LU0106261372.USD","LU0238689110.USD","SG9999015341.SGD","LU0058720904.USD","LU1934455194.USD","LU1983299246.USD","SG9999014559.SGD","ADAG","SG9999002224.SGD","IE0009355771.USD","LU1066053197.SGD","LU1934455277.USD","LU0203347892.USD","LU1989772923.USD","OS","IE00B4R5TH58.HKD","MSS","ORR","LU0266512127.USD","BK4550","SG9999014567.USD","LU1934455863.HKD","BK4139","PFS","LU1291159041.SGD","LU1061106388.HKD","BK4097","LU0265550359.USD","LU0965509010.AUD","SG9999001176.USD","BK4559","MRK","LU1035773651.USD","LU0211331839.USD"],"gpt_icon":0},{"id":"2579989166","title":"Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579989166","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579989166?lang=en_us&edition=fundamental","pubTime":"2025-10-30 11:51","pubTimestamp":1761796260,"startTime":"0","endTime":"0","summary":"BEIJING, Oct.  29, 2025  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177027/0/en/Latest-Data-of-InnoCare-s-Zurletrectinib-Orally-Presented-at-SIOP-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","ORR","PK","BK4218"],"gpt_icon":0},{"id":"2578288966","title":"MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578288966","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578288966?lang=en_us&edition=fundamental","pubTime":"2025-10-27 22:45","pubTimestamp":1761576300,"startTime":"0","endTime":"0","summary":"First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct.  27, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174761/0/en/MAIA-Biotechnology-Presents-Trial-in-Progress-Poster-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1584","BK4202","BK4588","NIC","BK4097","LENZ","LU0210528500.USD","BK4211","LU0572940350.SGD","BK4007","BK1184","LU0264606111.USD","NCI","BK4107","LU0572939691.SGD","BK1550","BK4139","LU2065732104.USD","MAIA","BK4539","LU2487616109.SGD","01336","BK4585","L","PRGS","ORR","CPI","LU0053666078.USD"],"gpt_icon":0},{"id":"2578058555","title":"Asylum seeker released in error seen in London area, police say","url":"https://stock-news.laohu8.com/highlight/detail?id=2578058555","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578058555?lang=en_us&edition=fundamental","pubTime":"2025-10-25 22:29","pubTimestamp":1761402586,"startTime":"0","endTime":"0","summary":"Responsibility for the manhunt has been handed over to the Metropolitan Police after it was confirmed that Kebatu was last seen getting off a train at Stratford in east London at around 13:10pm on Friday.Stay ahead with our three daily briefings delivering all the key market moves, top business and political stories, and incisive analysis straight to your inbox.“We will provide further updates when we can, but I hope the press and the public will understand why it would be unhelpful to the effectiveness of the manhunt if we were to provide a detailed running commentary.”Anyone who sees Kebatu, or has information his whereabouts, has been urged to call 999.No description of the offender, or what he is thought to be wearing has been released by police.Stratford station is the fifth busies","market":"us","thumbnail":"https://www.cityam.com/wp-content/uploads/2025/08/GettyImages-1475047893-e1754326684479.jpg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2025/08/GettyImages-1475047893-e1754326684479.jpg?w=824&h=463&crop=1"],"rights":{"source":"cityam_highlight","url":"https://www.cityam.com/asylum-seeker-released-in-error-seen-in-london-area-police-say/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/asylum-seeker-released-in-error-seen-in-london-area-police-say/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["BK4529","BK4084","ORR","BK4585","BK4222","DLR","BK4588","BK4566"],"gpt_icon":0},{"id":"2577434745","title":"PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation","url":"https://stock-news.laohu8.com/highlight/detail?id=2577434745","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577434745?lang=en_us&edition=fundamental","pubTime":"2025-10-24 23:39","pubTimestamp":1761320340,"startTime":"0","endTime":"0","summary":"Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in eight tumor types spanning ovar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3172959/0/en/PMV-Pharmaceuticals-Announces-Updated-Rezatapopt-Monotherapy-Interim-Data-From-Ongoing-PYNNACLE-Phase-2-Trial-Across-Multiple-Solid-Tumors-With-a-TP53-Y220C-Mutation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","ORR","BK4139","ALT","LU1878469433.USD","PMVP"],"gpt_icon":0},{"id":"2577958432","title":"Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577958432","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577958432?lang=en_us&edition=fundamental","pubTime":"2025-10-24 00:30","pubTimestamp":1761237000,"startTime":"0","endTime":"0","summary":"Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172321/0/en/Zymeworks-Presents-Initial-Clinical-Data-from-the-Phase-1-trial-of-ZW191-an-Antibody-Drug-Conjugate-Targeting-Folate-Receptor-at-AACR-NCI-EORTC-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1184","BK4590","LU0572940350.SGD","LU0572939691.SGD","NCI","BK4585","BK4561","BK1584","LU0264606111.USD","ORR","01336","BK4588","ET","BK4144","BK4581","BK4231","BK4080","BK1550","ADC","BK4202"],"gpt_icon":0},{"id":"2577330907","title":"BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2577330907","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577330907?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:00","pubTimestamp":1761220800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  23, 2025  (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172001/0/en/BioAtla-Presents-Compelling-Mechanistic-Rationale-for-Targeting-ROR2-with-Ozuriftamab-Vedotin-Oz-V-in-Oropharyngeal-Squamous-Cell-Carcinoma-OPSCC-at-the-Annual-Conference-of-the-In.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4097","ADC","BK4231","OS","ORR","BCAB","BK4139"],"gpt_icon":0},{"id":"2577305008","title":"Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2577305008","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577305008?lang=en_us&edition=fundamental","pubTime":"2025-10-23 19:00","pubTimestamp":1761217200,"startTime":"0","endTime":"0","summary":"– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3171895/0/en/Tango-Therapeutics-Reports-Positive-Data-from-Ongoing-Phase-1-2-Study-with-Vopimetostat-TNG462-in-Patients-with-MTAP-deleted-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861215975.USD","BK4512","ON","LU0348723411.USD","BK4605","LU1548497426.USD","LU2357305700.SGD","LU0724618433.USD","IE00BFMHRM44.USD","LU2360107325.USD","BK4588","IE00BZ199S13.USD","LU1978683503.SGD","ORR","LU1861214812.USD","RVMD","LENZ","LU0124384867.USD","LU1854104046.USD","LU2298322129.HKD","LU1854103824.USD","LU1720051108.HKD","BK4539","LU1720051017.SGD","LU1861219969.SGD","BK4141","LU1861220033.SGD","IE00BD6J9T35.USD","BK4139","TNGX","BK4007","BK4585"],"gpt_icon":0},{"id":"2577041394","title":"I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577041394","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577041394?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:35","pubTimestamp":1761150900,"startTime":"0","endTime":"0","summary":"Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171382/0/en/I-Mab-To-Present-Positive-Updated-Givastomig-Monotherapy-Data-at-2025-AACR-NCI-EORTC-Molecular-Targets-and-Cancer-Therapeutics-Conference-on-October-23-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264606111.USD","01336","NCI","BK4225","BK1584","BK1184","BK4213","LU0572939691.SGD","BK4202","IMAB","LU0572940350.SGD","ORR","LENZ","BK4535","SD","PR","BK4539","BK4526","BK4203","HR","BK4505","BK1550","BK4139","BK4007"],"gpt_icon":0},{"id":"2577873728","title":"CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2577873728","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577873728?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:15","pubTimestamp":1761048900,"startTime":"0","endTime":"0","summary":"Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct.  21, 2025  (GLOBE NEWSWIRE) --  CERo Therapeutics Hol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3170171/0/en/CERo-Therapeutics-Announces-Third-Dose-for-Patient-in-Phase-1-Clinical-Trial-of-CER-1236-in-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4161","CR","PK","ORR","BK4181","LENZ","BK4139","BK4218"],"gpt_icon":0},{"id":"2577846438","title":"SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2577846438","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577846438?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":"Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3169927/0/en/SpringWorks-Therapeutics-Announces-Publication-of-Long-Term-Efficacy-and-Safety-Data-from-the-Phase-3-DeFi-Trial-of-OGSIVEO-nirogacestat-in-Adults-with-Desmoid-Tumors-in-the-Journa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","LU0203345920.USD","BK4588","LU0965509283.SGD","SG9999002224.SGD","LU0289739699.SGD","LU2112291526.USD","LU1929549753.HKD","LU1023059063.AUD","LU1917777945.USD","LU1974910355.USD","PFS","IE0009355771.USD","LU0211331839.USD","LU1066051225.USD","BK4516","LU1989772923.USD","SG9999001440.SGD","LU0070302665.USD","LU0203347892.USD","BK4534","SG9999014559.SGD","IE00B2B36J28.USD","BK4139","LU1430594728.SGD","LU1093756168.USD","SG9999001176.USD","LU0122379950.USD","PRO","BK4585","IE00BFTCPJ56.SGD","BK4007","SG9999002232.USD","LU1066051498.USD","LU0208291251.USD","LU0965509101.SGD","BK4559","IE00BBT3K403.USD","SG9999013999.USD","LU1035773651.USD","LU1934455863.HKD","LU1941712264.USD","LU2023250843.SGD","MRK","BK4533","LENZ","IE0002141913.USD","LU1983299246.USD","LU1069347547.HKD","ORR"],"gpt_icon":0},{"id":"2577464328","title":"SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2577464328","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577464328?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:00","pubTimestamp":1761026400,"startTime":"0","endTime":"0","summary":"– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/21/3169940/0/en/SpringWorks-Therapeutics-Announces-Publication-of-Long-Term-Efficacy-and-Safety-Data-from-the-Phase-3-DeFi-Trial-of-OGSIVEO-nirogacestat-in-Adults-with-Desmoid-Tumors-in-the-Journa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","SG9999002232.USD","LU1069347547.HKD","LU0320765489.SGD","LU1430594728.SGD","LU0965509101.SGD","SG9999013999.USD","LU2324357040.USD","LU1061106388.HKD","BK4023","LU2106854487.HKD","BK4195","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1989772923.USD","LENZ","LU1291159041.SGD","LU0203347892.USD","IE00B1BXHZ80.USD","MRK","LU1983299246.USD","IE0009355771.USD","PFS","SG9999001176.SGD","SG9999014567.USD","LU1035773651.USD","LU1941712348.USD","LU0211331839.USD","LU0122379950.USD","LU1066051225.USD","BK4007","LU0098860793.USD","IE00B2B36J28.USD","LU1917777945.USD","LU1116320901.HKD","LU1585245621.USD","LU0203345920.USD","LU0266013472.USD","LU0106261372.USD","BK4585","SG9999015358.SGD","ORR","PRO","IE00BLSP4452.SGD","LU2023250843.SGD","IE00BN8TJ469.HKD","LU1162221912.USD","IE00BBT3K403.USD","SG9999014559.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2577869274","title":"Verastem: GFH375 resulted in 41% ORR in Phase 1/2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2577869274","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577869274?lang=en_us&edition=fundamental","pubTime":"2025-10-21 00:10","pubTimestamp":1760976624,"startTime":"0","endTime":"0","summary":"Verastem (VSTM) Oncology on Sunday announced updated efficacy and safety data from partner GenFleet Therapeutics’ Phase 1/2 monotherapy study in Ch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verastem-gfh375-resulted-in-41-orr-in-phase-1-2-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verastem-gfh375-resulted-in-41-orr-in-phase-1-2-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORR","BK4139","VSTM"],"gpt_icon":0},{"id":"2577552861","title":"Why Is Genmab Stock Trading Lower On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577552861","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577552861?lang=en_us&edition=fundamental","pubTime":"2025-10-20 23:57","pubTimestamp":1760975820,"startTime":"0","endTime":"0","summary":"Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/20/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/20/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48308963/why-is-genmab-stock-trading-lower-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48308963/why-is-genmab-stock-trading-lower-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4588","BK4161","LU0210528500.USD","BK4107","LU2487616109.SGD","GMAB","CR","LU0053666078.USD","BK4585","L","ORR","BK4139"],"gpt_icon":0},{"id":"2576786358","title":"What's Going On With Summit Therapeutics Stock On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576786358","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576786358?lang=en_us&edition=fundamental","pubTime":"2025-10-20 22:05","pubTimestamp":1760969100,"startTime":"0","endTime":"0","summary":"Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/20/Summit-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/20/Summit-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48303693/whats-going-on-with-summit-therapeutics-stock-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48303693/whats-going-on-with-summit-therapeutics-stock-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SG9999001176.USD","LU1989772923.USD","LU2361045086.USD","IE00BLSP4239.USD","LU0208291251.USD","LU1989772840.SGD","SMMF","LU1066053197.SGD","LU1571399168.USD","LU1934455277.USD","SGXZ57979304.SGD","LU1037948897.HKD","LU2023250504.SGD","LU2468319806.SGD","LU1057294990.SGD","MRK","ONC","IE000M9KFDE8.USD","LU0965508806.USD","LENZ","LU0058720904.USD","LU1929549753.HKD","LU2361044865.SGD","ORR","LU0070302665.USD","SMMT","LU0289739699.SGD","BK4539","BK4533","LU0965509010.AUD","LU0234572021.USD","BK4211","LU1093756325.SGD","LU2361044949.HKD","BK4534","BK4516","LU1974910355.USD","LU0456854461.SGD","IE00BFTCPJ56.SGD","LU1066051498.USD","IE00BJT1NW94.SGD","LU0006306889.USD","LU0265550359.USD","LU1989771016.USD","SG9999014542.SGD","CRC","BK4139","LU1093756168.USD","LU0861579265.USD","SG9999001440.SGD"],"gpt_icon":0},{"id":"2576064851","title":"Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064851","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064851?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:00","pubTimestamp":1760961600,"startTime":"0","endTime":"0","summary":"Novel combination of efti with KEYTRUDA and chemotherapy generates strong response rates across all PD-L1 expression levels in first line non-small cell lung cancer (1L NSCLC) including 61.7% ORR in l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169319/0/en/Two-Posters-at-ESMO-Congress-2025-Highlight-Immutep-s-Focus-on-Changing-Treatment-Landscape-in-First-Line-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051811.HKD","LU0965508806.USD","SG9999013999.USD","BK4533","LU0965509101.SGD","LU1974910355.USD","BK4559","LU2361045086.USD","LU1116320901.HKD","LU2461242641.AUD","MRK","LU1430594728.SGD","SG9999014567.USD","LU2468319806.SGD","INAQU","LU0320765646.SGD","BK4007","LU2324357040.USD","SG9999001440.SGD","LU1057294990.SGD","IE00BN8TJ469.HKD","SG9999014542.SGD","IMMP","LU1162221912.USD","IE000M9KFDE8.USD","LU1941712348.USD","SG9999014559.SGD","LU0208291251.USD","LU2106854487.HKD","LU1941712264.USD","LU0238689110.USD","ORR","LU0265550946.USD","LU0058720904.USD","IE00BSNM7G36.USD","L","LU1023059063.AUD","IE00BLSP4239.USD","LU1035773651.USD","LU0265550359.USD","BK4516","LU0122379950.USD","LU0985320562.USD","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU1069347547.HKD","LU1037948897.HKD","LU0211331839.USD","LU2487616109.SGD","LU0070302665.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":140,"code":"91000000","status":"200"}]}}